|
WO1995003009A1
(en)
|
1993-07-22 |
1995-02-02 |
Oculex Pharmaceuticals, Inc. |
Method of treatment of macular degeneration
|
|
WO1995003807A1
(en)
|
1993-07-27 |
1995-02-09 |
The University Of Sydney |
Treatment of age-related macular degeneration
|
|
US5801195A
(en)
*
|
1994-12-30 |
1998-09-01 |
Celgene Corporation |
Immunotherapeutic aryl amides
|
|
IT1274549B
(it)
|
1995-05-23 |
1997-07-17 |
Indena Spa |
Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno
|
|
US5800819A
(en)
|
1996-01-25 |
1998-09-01 |
National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology |
Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease
|
|
DE69740140D1
(de)
|
1996-07-24 |
2011-04-14 |
Celgene Corp |
Substituierte 2-(2,6-Dioxopiperidin-3-yl)-phthalimide und Oxoisoindoline und Verfahren zur Verringerung der TNF-Alpha-Stufen
|
|
US5635517B1
(en)
|
1996-07-24 |
1999-06-29 |
Celgene Corp |
Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
|
|
US6281230B1
(en)
|
1996-07-24 |
2001-08-28 |
Celgene Corporation |
Isoindolines, method of use, and pharmaceutical compositions
|
|
HU228769B1
(en)
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
|
HN1998000115A
(es)
|
1997-08-21 |
1999-06-02 |
Warner Lambert Co |
Formas de dosificación farmacéuticas sólidas
|
|
US6015803A
(en)
|
1998-05-04 |
2000-01-18 |
Wirostko; Emil |
Antibiotic treatment of age-related macular degeneration
|
|
US6225348B1
(en)
|
1998-08-20 |
2001-05-01 |
Alfred W. Paulsen |
Method of treating macular degeneration with a prostaglandin derivative
|
|
US6001368A
(en)
|
1998-09-03 |
1999-12-14 |
Protein Technologies International, Inc. |
Method for inhibiting or reducing the risk of macular degeneration
|
|
US6667316B1
(en)
*
|
1999-11-12 |
2003-12-23 |
Celgene Corporation |
Pharmaceutically active isoindoline derivatives
|
|
US7182953B2
(en)
|
1999-12-15 |
2007-02-27 |
Celgene Corporation |
Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
|
|
US20040190609A1
(en)
|
2001-11-09 |
2004-09-30 |
Yasuhiko Watanabe |
Moving picture coding method and apparatus
|
|
US20100129363A1
(en)
|
2002-05-17 |
2010-05-27 |
Zeldis Jerome B |
Methods and compositions using pde4 inhibitors for the treatment and management of cancers
|
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
|
US7323479B2
(en)
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
US7189740B2
(en)
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
|
US20050203142A1
(en)
|
2002-10-24 |
2005-09-15 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
|
|
US20040091455A1
(en)
|
2002-10-31 |
2004-05-13 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
|
|
US7563810B2
(en)
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
|
US20050100529A1
(en)
|
2003-11-06 |
2005-05-12 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
|
|
BRPI0417186A
(pt)
|
2003-12-02 |
2007-03-06 |
Celgene Corp |
método de tratamento de um indivìduo tendo uma hemoglobinopatia ou uma anemia, de modulação da diferenciação de uma célula-tronco ou precursora de cd34+ para uma linhagem de eritróides, e, composição farmacêutica
|
|
US20050143344A1
(en)
|
2003-12-30 |
2005-06-30 |
Zeldis Jerome B. |
Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
|
|
AU2005226649B2
(en)
|
2004-03-22 |
2010-04-29 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
|
|
US20050222209A1
(en)
|
2004-04-01 |
2005-10-06 |
Zeldis Jerome B |
Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
|
|
BRPI0510110A
(pt)
|
2004-04-23 |
2007-09-25 |
Celgene Corp |
método para tratar, prevenir ou controlar hipertensão pulmonar, e, composição farmacêutica
|
|
EP1817008B1
(en)
*
|
2004-11-09 |
2020-04-01 |
Board of Regents, The University of Texas System |
Stabilized hme composition with small drug particles
|
|
WO2006053160A2
(en)
|
2004-11-12 |
2006-05-18 |
Celgene Corporation |
Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases
|
|
CN101102771A
(zh)
|
2004-11-23 |
2008-01-09 |
细胞基因公司 |
用免疫调节化合物治疗和控制中枢神经系统损伤的方法和组合物
|
|
PL1928492T3
(pl)
|
2005-09-01 |
2011-09-30 |
Celgene Corp |
Immunologiczne zastosowania związków immunomodulujących do szczepionki i przeciwzakaźnego leczenia choroby
|
|
JP2010526848A
(ja)
*
|
2007-05-11 |
2010-08-05 |
エフ．ホフマン−ラ ロシュ アーゲー |
難溶性薬物用の医薬組成物
|
|
US20110053942A1
(en)
*
|
2008-02-13 |
2011-03-03 |
Dainippon Sumitomo Pharma Co., Ltd. |
Orally disintegrating tablets
|
|
WO2009120296A1
(en)
*
|
2008-03-24 |
2009-10-01 |
Celgene Corporation |
Treatment of psoriasis or psoriatic arthritis using cyclopropyl-n-{2-{(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
|
|
CA2734646C
(en)
|
2008-08-20 |
2016-06-28 |
James W. Mcginity |
Hot-melt extrusion of modified release multi-particulates
|
|
WO2010030345A2
(en)
|
2008-09-10 |
2010-03-18 |
Celgene Corporation |
Processes for the preparation of aminosulfone compounds
|
|
MY160002A
(en)
|
2009-02-10 |
2017-02-15 |
Celgene Corp |
Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis
|
|
CA2780292A1
(en)
|
2009-11-10 |
2011-05-19 |
Celgene Corporation |
Nanosus pens ion of a poorly soluble drug made by microfluidization process
|
|
MX337603B
(es)
*
|
2009-11-30 |
2016-03-10 |
Adare Pharmaceuticals Inc |
Composiciones y tabletas farmaceuticas con recubrimiento compresible y metodos de fabricacion.
|
|
ES2632979T3
(es)
|
2011-01-10 |
2017-09-18 |
Celgene Corporation |
Formas de dosificación oral de {2-[(1S)-1-(3-etoxi-4-metoxi-fenil)-2-metanosulfonil-etil]-3-oxo-2,3-dihidro-1H-isoindol-4-il}-amida de ácido ciclopropanocarboxílico
|
|
CA2848493A1
(en)
|
2011-09-14 |
2013-03-21 |
Celgene Corporation |
Formulations of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amide
|
|
AU2012362562B2
(en)
|
2011-12-27 |
2017-11-02 |
Amgen (Europe) GmbH |
Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
|